Oncology Clinical Trials in Los Angeles, CA

As of September 2026, 436 paid clinical trials are recruiting for Oncology in Los Angeles, California. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

438 clinical trials for Oncology

·Clear filters·

Email me when a new oncology trial opens in Los Angeles, CA.

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

Drug: Intismeran autogene

Sites in Los Angeles, Long Beach +48 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

Drug: sigvotatug vedotin

Sites in Los Angeles, Santa Monica +102 more locations

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting·Listed May 2020

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

Sites in Los Angeles, Orange +56 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

Drug: Divarasib

Sites in Los Angeles, Newport Beach +52 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06793215·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Daratumumab

Sites in Los Angeles, Los Alamitos +64 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

Drug: Zongertinib

Sites in Los Angeles, Cerritos +24 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for Ovarian Cancer

Drug: INCB123667

Sites in Los Angeles, San Diego +36 more locations

Sponsor: Incyte Corporation

Sex: Female·Age: 18 - 99

Code: NCT07023627·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

Sites in Los Angeles, Santa Barbara +35 more locations

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

Sites in Los Angeles, Santa Monica +56 more locations

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for Non Small Cell Lung Cancer

Sites in Los Angeles, Beverly Hills +42 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312137·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

Sites in Los Angeles, Long Beach +47 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

FOG-001 in Locally Advanced or Metastatic Solid Tumors

for Cancer

Sites in Los Angeles, Santa Monica +28 more locations

Sponsor: Parabilis Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05919264·Phase 1, Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

for Advanced Solid Tumor

Sites in Los Angeles, Beverly Hills +22 more locations

Sponsor: Synthekine

Sex: All·Age: 18+

Code: NCT05098132·Phase 1, Phase 2·Recruiting·Listed Oct 2021

Apply to this trial

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for Hormone Receptor Positive HER-2 Negative Breast Cancer

Sites in Los Angeles, Beverly Hills +32 more locations

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06369285·Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

for Breast Cancer

Sites in Los Angeles, Glendale +100 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07062965·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for Relapsed Non-Hodgkin Lymphoma

Sites in Los Angeles, Irvine +30 more locations

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT05826535·Phase 1, Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

for Colorectal Cancer

Sites in Los Angeles, Whittier +30 more locations

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT06562543·Phase 4·Recruiting·Listed Aug 2024

Apply to this trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for AML

Sites in Los Angeles, Orange +34 more locations

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06001788·Phase 1·Recruiting·Listed Aug 2023

Apply to this trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

for Prostate Cancer

Drug: JANX007

Sites in Los Angeles, Newport Beach +31 more locations

Sponsor: Janux Therapeutics

Sex: Male·Age: 18 - 100

Code: NCT05519449·Phase 1·Recruiting·Listed Aug 2022

Apply to this trial

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

for Colorectal Cancer

Sites in Los Angeles, La Jolla +30 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06445062·Phase 1, Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

for Neoplasms

Sites in Los Angeles, Orange +23 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 1 - 39

Code: NCT05999994·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for Small Cell Lung Cancer

Sites in Los Angeles, Fullerton +28 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06203210·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for Myelofibrosis

Sites in Los Angeles, Duarte +28 more locations

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT04176198·Phase 1, Phase 2·Recruiting·Listed Nov 2019

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

Sites in Los Angeles, Van Nuys +132 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Sites in Los Angeles, Orange +21 more locations

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT04302025·Phase 2·Recruiting·Listed Mar 2020

Apply to this trial

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

for Breast Cancer

Sites in Los Angeles, San Francisco +22 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05768139·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

for Myelodysplastic Syndrome

Sites in Los Angeles, Duarte +39 more locations

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04227847·Phase 1·Recruiting·Listed Jan 2020

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

for Non-Small Cell Lung Cancer

Drug: Ivonescimab

Sites in Los Angeles, Beverly Hills +92 more locations

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT06767514·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

for Head and Neck Squamous Cell Carcinoma

Sites in Los Angeles, Duarte +27 more locations

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT06163534·Recruiting·Listed Dec 2023

Apply to this trial

A Phase 1/1b Study of IAM1363 in HER2 Cancers

for HER2 Mutation-Related Tumors

Sites in Los Angeles, La Jolla +27 more locations

Sponsor: Iambic Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06253871·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

for Prostate Cancer

Sites in Los Angeles, Santa Monica +25 more locations

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT06780670·Phase 2, Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Sites in Los Angeles, San Francisco +36 more locations

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

for Prostate Cancer

Sites in Los Angeles, Orange +25 more locations

Sponsor: Clarity Pharmaceuticals Ltd

Sex: Male·Age: 18+

Code: NCT06056830·Phase 3·Recruiting·Listed Sep 2023

Apply to this trial

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

for Chronic Lymphocytic Leukemia

Drug: Venetoclax

Sites in Los Angeles, Clovis +29 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06428019·Phase 3·Recruiting·Listed May 2024

Apply to this trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

for Multiple Myeloma

Drug: Elranatamab

Sites in Los Angeles, Beverly Hills +91 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06152575·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

GEMINI-NSCLC: NSCLC Biomarker Study

for Non-Small Cell Lung Cancer

Sites in Los Angeles, Fountain Valley +54 more locations

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT05236114·Recruiting·Listed Feb 2022

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

Sites in Los Angeles, Orange +42 more locations

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

Sites in Los Angeles, La Jolla +29 more locations

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020

Apply to this trial

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

for Epithelial Ovarian Cancer

Sites in Los Angeles, Duarte +24 more locations

Sponsor: TORL Biotherapeutics, LLC

Sex: Female·Age: 18+

Code: NCT06690775·Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

Sites in Los Angeles, Torrance +56 more locations

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Conditions in Oncology (Los Angeles, CA)

Solid tumor· 83 Non-small cell lung cancer (NSCLC)· 62 Breast cancer· 53 Cancer (any)· 43 Prostate cancer· 40 Colorectal cancer· 39 Pancreatic cancer· 34 Ovarian cancer· 27 Head and neck cancer· 22 Bladder cancer· 21 Endometrial cancer· 20 Melanoma· 19 Lung cancer· 16 Acute myeloid leukemia (AML)· 16 Gastric cancer· 15 Esophageal cancer· 14 Hematologic malignancy· 14 Glioblastoma· 13 Multiple myeloma· 13 Triple-negative breast cancer· 12 Liver cancer· 12 Kidney cancer· 12 Metastatic prostate cancer· 11 Cervical cancer· 11 Diffuse large B-cell lymphoma (DLBCL)· 11 Metastatic breast cancer· 10 Biliary tract cancer· 10 Leukemia (other)· 10 Myelodysplastic syndromes (MDS)· 9 Colon cancer· 8 Non-Hodgkin lymphoma· 8 Gastroesophageal junction cancer· 7 Neuroblastoma· 7 Glioma· 6 Chronic lymphocytic leukemia (CLL)· 6 Acute lymphoblastic leukemia· 6 Small cell lung cancer· 5 Fallopian tube cancer· 5 Ewing sarcoma· 5 Metastatic colorectal cancer· 4 Rectal cancer· 4 Brain cancer· 4 Myelofibrosis· 4 Mantle cell lymphoma· 4 Thyroid cancer· 4 Osteosarcoma· 4 Pediatric cancer· 4 HER2-positive breast cancer· 3 HER2-negative breast cancer· 3 Gastrointestinal cancer· 3 Chronic myelomonocytic leukemia· 3 Small lymphocytic lymphoma· 3 Skin cancer· 3 Mesothelioma· 3 Brain metastases· 2 Myeloproliferative neoplasm· 2 Hodgkin lymphoma· 2 Follicular lymphoma· 2 Burkitt lymphoma· 2 Sarcoma· 2 Soft tissue sarcoma· 2 Uterine cancer· 1 Marginal zone lymphoma· 1 Rhabdomyosarcoma· 1 Neuroendocrine tumors· 1